Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Launch of Novel Products to Boost the Sepsis Diagnostics Market | Technavio

Technavio Research
Posted on: 31 Oct 17

Technavio’s latest market research report on the global sepsis diagnostics marketprovides an analysis of the most important trends expected to impact the market outlook from 2017-2021. Technaviodefines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171031006394/en/

Technavio has published a new report on the global sepsis diagnostics market from 2017-2021. (Graphic: Business Wire)

Sepsis is a three-staged syndrome; it starts with systemic infections leading to severe sepsis and ultimately causing sepsis shock, which is regarded as a medical emergency. Population with weak immune system, which includes children, older adults, and people with chronic diseases such as cancer, AIDS, diabetes, are prone to sepsis. The global sepsis diagnostics market will grow at a CAGR of close to 7% during the forecast period, as companies are focusing on providing accurate treatment for sepsis by launching new products in the market.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

The top three emerging trends driving the global sepsis diagnostics market according to Technavio research analysts are:

  • Development of novel products
  • Increasing use of biomarkers for sepsis
  • Increasing online campaigns for sepsis awareness

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Development of novel products

Increased technological advances in sepsis diagnosis will lead to a rise in the customer base, thereby increasing the adoption rate of products. For instance, in May 2017, Abionic, a developer of disrupter nanotechnology in POC diagnostic solutions, announced positive results from its evaluation studies with its rapid PSP tests for sepsis risk assessment, which was conducted at Zurich University Hospital (Switzerland) and University College London Hospital (UK). The product offers reliable results, showing an indication of sepsis in 5 minutes. Similarly, in March 2015, T2 Biosystems developed a novel diagnostic method for sepsis known as T2Candida equipment, which does not require blood culture. This will reduce the diagnosis time by 97% and is estimated to decrease mortality rate by 30%.

According to Srinivas Sashidhar, a lead analyst at Technavio forin-vitro diagnostics research, “The availability of advanced products for detection of the risk assessment of sepsis will help in decreasing the TAT and will increase the efficiency of the quality of test results, which augurs well for the growth of the market.”

Increasing use of biomarkers for sepsis

Biomarkers are used as diagnostic tools for the diagnosis of a disease or abnormal conditions of sepsis, including severe sepsis. The accuracy and timely detection of sepsis are regarded as the significant challenges. Therefore, the health providers rely on nonspecific clinical and laboratory signs. The increased preference for biomarkers offers homogeneity of risk or disease status of the patient within a limited time.

More than 100 different molecules have been suggested as useful biomarkers for the treatment of sepsis, which include C-reactive protein (CRP), procalcitonin (PCT), angiopoietins, endocans, and others. The use of biomarkers also reduced the cost of hospital stay, and the procedure was cost-effective. Therefore, they can be utilized in-patient diagnosis and treatment routinely.

Increasing online campaigns for sepsis awareness

The increasing awareness of sepsis diagnosis within the population will lead to the high adoption of the sepsis diagnostics. Various campaigns organized to educate the patients will lead to more screening of the patients, thereby creating a demand for sepsis products in the market. For instance, in the US, the CDC launched a new website known as Surviving Sepsis Campaign to increase sepsis awareness which will help in early recognition, diagnosis, and treatment of sepsis.

“The sepsis awareness website offers thorough and extensive information on diagnosis and screening of sepsis which offers valuable information, and it encourages people to get examined for sepsis. Such campaigns will help in educating people and creating awareness, which in turn, will boost the sepsis diagnostic market during the forecast period,” says Srinivas.

Browse Related Reports:

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171031006394/en/

Business Wire
www.businesswire.com

Last updated on: 31/10/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.